Journal of Neurology

, Volume 259, Issue 2, pp 237–245

Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis

  • T. Hayton
  • J. Furby
  • K. J. Smith
  • D. R. Altmann
  • R. Brenner
  • J. Chataway
  • K. Hunter
  • D. J. Tozer
  • D. H. Miller
  • R. Kapoor
Original Communication

Abstract

The association of pathology and neurological deficit with quality of life (QoL) in multiple sclerosis (MS) is not fully understood. In this study, magnetic resonance imaging (MRI) measures of pathology—T1 and T2 lesion volume and ratio; active T2 lesion number; global and regional brain volume and atrophy; magnetization transfer ratio (MTR) for lesions, normal appearing grey and white matter (NAGM, NAWM); and spinal cord cross-sectional area—and measures of neurological disability (expanded disability status scale, EDSS), deficit (MS functional composite, MSFC) and inflammatory activity (relapse rate) were compared with the MS impact scale (MSIS-29), in participants in a trial of lamotrigine in secondary progressive MS. Data were collected from 118 people (85 female:33 male) aged 30–61 years (mean 50.6 years)—median EDSS 6.0 (range 4.0–7.5); mean disease duration 20.1 years (range 3–41)—at baseline and 2 years. Regression analysis was used to identify independently significant cross-sectional and longitudinal correlates of the physical (MSIS-phys) and psychological (MSIS-psych) components of the MSIS-29; longitudinal analysis using the 57 people in the placebo arm. The only independently significant correlate of MSIS-phys was 1/timed walk (TW) (p < 0.0001, R2 = 0.13; p = 0.047, R2 = 0.09); cross-sectionally the best model for MSIS-psych was the paced auditory serial addition test (PASAT-3) (p = 0.041) and T1-to-T2 lesion volume ratio (p = 0.009) (R2 = 0.13); longitudinally it was change in 1/TW (p = 0.007), mean NAWM MTR (p = 0.003) and NAGM peak height (p = 0.048) (R2 = 0.32). These data show that MRI measures and clinical measures do impact on quality of life, but the association is limited.

Keywords

Multiple sclerosis MRI Secondary progressive MSIS-29 

References

  1. 1.
    Confavreux C, Vukusic S, Moreau T, Adelein P (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343:1430–1438PubMedCrossRefGoogle Scholar
  2. 2.
    Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, Edan G (2010) Evidence for a two-stage disability progression in multiple sclerosis. Brain 133:1900–1913PubMedCrossRefGoogle Scholar
  3. 3.
    Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro A, Daumer M, Ebers GC (2010) The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain 133:1914–1929PubMedCrossRefGoogle Scholar
  4. 4.
    Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in lesions of multiple sclerosis. N Engl J Med 338:278–285PubMedCrossRefGoogle Scholar
  5. 5.
    Kutzelnigg A, Luchinetti CF, Stadelman C, Bruck W, Rauschka H, Bermann M, Schmidbauer M, Parisi JE, Lassman H (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128:2705–2712PubMedCrossRefGoogle Scholar
  6. 6.
    Miller DH, Barkhof F, Frank JA, Parker GJM, Thompson AJ (2002) Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 125:1676–1695PubMedCrossRefGoogle Scholar
  7. 7.
    Li DKB, Held U, Petkau J, Daumer M, Barkhof F, Fazekas F, Frank JA, Kappos L, Miller DH, Simon JH, Wolinsky JS, Filippi M, and for the Sylvia Lawry Centre for MS Research MRI (2006) T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology 66:1384–1389PubMedCrossRefGoogle Scholar
  8. 8.
    Filippi M, Agosta F. (2007) Magnetization transfer MRI in multiple sclerosis. J Neuroimaging. Suppl 1:22S-26SGoogle Scholar
  9. 9.
    Rothwell PM, McDowell D, Wong CK, Dornan PJ (1997) Doctors and patients don’t agree: cross-sectional study of patients’ and doctors’ perceptions and assessments of disability in multiple sclerosis. BMJ 314:1580–1583PubMedCrossRefGoogle Scholar
  10. 10.
    Newcombe J, Hawkins CP, Henderson CL, Patel HA, Woodroofe MN, Hayes GM, Cuzner ML, MacManus D, du Boulay EP, McDonald WI (1991) Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue. Brain 114:1013–1023PubMedCrossRefGoogle Scholar
  11. 11.
    Naismith RT, Cross AH (2005) Multiple sclerosis and black holes: connecting the pixels. Arch Neurol 62:1666–1668PubMedCrossRefGoogle Scholar
  12. 12.
    Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452PubMedGoogle Scholar
  13. 13.
    Fischer JS, Rudick RA, Cutter GR, Reingold SC, The national MS society clinical outcomes assessment task force (1999) The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult Scler 5:244–250PubMedGoogle Scholar
  14. 14.
    Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A (2001) The multiple sclerosis impact scale: a new patient-based outcome measure. Brain 124:962–973PubMedCrossRefGoogle Scholar
  15. 15.
    Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Thompson AJ (2002) Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples. J Neurol Neurosurg Psychiatr 73:701–704PubMedCrossRefGoogle Scholar
  16. 16.
    Hoogervorst ELJ, Zwemmer JNP, Jelles B, Polman CH, Uitdehaag BMJ (2004) Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability. Mult Scler 10:569–574PubMedCrossRefGoogle Scholar
  17. 17.
    Costelloe L, O’Rourke K, McGuigan C, Walsh C, Tubridy N, Hutchinson M (2008) The longitudinal relationship between the patient-reported Multiple Sclerosis Impact Scale and the clinician-assessed Multiple Sclerosis Functional Composite. Mult Scler 14:255–258PubMedCrossRefGoogle Scholar
  18. 18.
    Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, Chataway J, Hughes RA, Miller DH (2010) A randomized controlled trial of neuroprotection with lamotrigine in secondary progressive multiple sclerosis. Lancet Neurol 9:681–688PubMedCrossRefGoogle Scholar
  19. 19.
    Cutter GR, Baier MS, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Synulko K, Weinshenker BG, Antel JP, Confavreaux C, Ellison GW, Lublin F, Miller AE, Rao SM, Reingold S, Thompson A, Willoughby E (1999) Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122:871–882PubMedCrossRefGoogle Scholar
  20. 20.
    Plummer DL (1992) Dispimage: a display and analysis tool for medical images. Revsita Di Neuroradiologica 5:489–495Google Scholar
  21. 21.
    Molyneux PD, Miller DH, Filippi M, Yousry TA, Radii EV, Ader HJ, Barkhof F (1999) Visual analysis of serial T2-weighted MRI in multiple sclerosis: intra- and interobserver reproducibility. Neuroradiology 41:882–888PubMedCrossRefGoogle Scholar
  22. 22.
    Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, De Stefano N (2002) Accurate, robust and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17:479–489PubMedCrossRefGoogle Scholar
  23. 23.
    Losseff NA, Webb SL, O’Riordan JI, Page R, Wang L, Barker GJ, Tofts PS, McDonald WI, Miller DH, Thompson AJ (1996) Spinal cord atrophjy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 119:701–708PubMedCrossRefGoogle Scholar
  24. 24.
    Furby J, Hayton T, Altmann D, Brenner R, Chataway J, Smith KJ, Miller DH, Kapoor R (2010) A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis. J Neurol 257:1508–1516PubMedCrossRefGoogle Scholar
  25. 25.
    Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi (2000) The effect of interferon Beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on interferon beta-b in secondary progressive multiple sclerosis. Brain 123:2256–2263PubMedCrossRefGoogle Scholar
  26. 26.
    CAMMS223 Trial Investigators (2008) Alemtuzumab vs interferon beta -1a in earlt multiple sclerosis. N Eng J Med 359:1786–1801CrossRefGoogle Scholar
  27. 27.
    Hayton T, Furby J, Smith KJ, Altmann DR, Brenner R, Chataway J, Hughes RAC, Hunter K, Tozer D, Miller DH, Kapoor R (2009) Grey matter magnetization transfer ratio independently correlates with neurological deficit in secondary progressive multiple sclerosis. J Neurol 256:427–435PubMedCrossRefGoogle Scholar
  28. 28.
    Ash burner J, Friston KJ (2005) Unified segmentation. Neuroimage 26:839–851CrossRefGoogle Scholar
  29. 29.
    Losseff NA, Wang L, Lau HM, Yoo DS, Gawne-Cain ML, McDonald WI, Miller DH, Thompson AJ (1996) Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 119:2009–2019PubMedCrossRefGoogle Scholar
  30. 30.
    Ebers GC, Heigenhauser L, Daumer M, Lederer C, Noseworthy JH (2008) Disability as an outcome in MS clinical trials. Neurology 7:624–631CrossRefGoogle Scholar
  31. 31.
    Benito-Leon JN, Morales JM, Rivera-Navarro JS, Mitchell AJ (2003) A review about the impact of multiple sclerosis on health-related quality of life. Disabil Rehabil 25:1291–1303PubMedCrossRefGoogle Scholar
  32. 32.
    Janhardan V, Bakshi R (2000) Quality of life and its relationship to brain lesions and atrophy on magnetice resonance images in 60 patients with multiple sclerosis. Arch Neurol 57:1485–1490CrossRefGoogle Scholar
  33. 33.
    Lobentanz IS, Asenbaum S, Vass K, Sauter C, Klosch G, Kollegger H, Kristoferitsch W, Zeitlhofer J (2004) Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality. Acta Neurol Scand 110:6–13PubMedCrossRefGoogle Scholar
  34. 34.
    Isaksson A-K, Ahlstrom G, Gunnarsson L-G (2005) Quality of life in patients with multiple sclerosis. J Neurol Neurosurg Psychiatr 76:64–69PubMedCrossRefGoogle Scholar
  35. 35.
    Simeoni MC, Auquier P, Fernandez O, Flachenecker P, Stecchi S, Constaninescu C, Idiman E, Boyko A, Beiske AG, Vollmer T, Triantafylliou N, O’Connor P, Barak Y, Beirmann L, Cristiano E, Atweh S, Patrick DL, Robitail S, Ammoury N, Beresniak A, Pelletier J, on behalf of the MusiQol study group (2008) Validation of the multiple sclerosis international quality of life questionnaire. Mult Scler 14:219–230PubMedCrossRefGoogle Scholar
  36. 36.
    Nordvedt MW, Riise T, Myhr K-M, Nyland HI (2000) Performance of the SF-36, SF-12 and Rand-36 summary scales in a multiple sclerosis population. Med Care 10:1022–1028CrossRefGoogle Scholar
  37. 37.
    Gold SM, Heeson C, Schultz H, Guder U, Monch A, Gbadamosi J, Buhmann C, Schultz KH (2001) Disease specific quality of life instruments in multiple sclerosis: validation of the Hamburg Quality of Life Questionnaire in multiple sclerosis (HAQUAMS). Mult Scler 7:119–130PubMedGoogle Scholar
  38. 38.
    Benito-Leon J, Morales JM, Riviera-Navarro J (2002) European journal of neurology health-related quality of life and its relationship to cognitive and emotional functioning in multiple sclerosis patients. Eur J Neurol 9:497–502PubMedCrossRefGoogle Scholar
  39. 39.
    Benedict RH, Wahlig E, Bakshi R, Fishman I, Munschauer F, Zivadinov R, Weinstock-Guttman B (2005) Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci 231:29–34PubMedCrossRefGoogle Scholar
  40. 40.
    Mitchell AJ, Benito-León J, Morales González J-M, Rivera-Navarro J (2005) Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol 4:556–566PubMedCrossRefGoogle Scholar
  41. 41.
    Ytterberg C, Johansson S, Holmqvist LW, von Koch L (2008) Longitudinal variations and predictors of increased perceived impact of multiple sclerosis, a two-year study. J Neurol Sci 270:53–59PubMedCrossRefGoogle Scholar
  42. 42.
    Mowry EM, Beheshtian A, Waubant E, Goodin DS, Cree BA, Qualley P, Lincoln R, George MF, Gomez R, Hauser SL, Okuda DT, Pelletier D (2009) Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology 72:1760–1765PubMedCrossRefGoogle Scholar
  43. 43.
    van Walderveen MAA, Kamphorst W, Scheltens P, van Waesberghe JHTM, Ravid R, Valk J, Polman CH, Barkhof F (1998) Histopathologic correlate of hypointense spin-echo lesions on Tl-weighted MRI in multiple sclerosis. Neurology 50:1282–1288PubMedGoogle Scholar
  44. 44.
    van Waesberghe JHTM, Kamphorst W, De Groot CJA, van Walderveen MAA, Castelijns JA, Ravid R, Lycklama a Nijeholt GJ, van der Valk P, Polman CH, Thompson AJ, Barkhof F (1999) Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 46:747–754PubMedCrossRefGoogle Scholar
  45. 45.
    Fisher E, Chang A, Fox RJ, Tkach JA, Svarovsky T, Nakamura K, Rudick RA, Trapp BD (2007) Imaging correlates of axonal swelling in chronic multiple sclerosis brains. Ann Neurol 62:219–228PubMedCrossRefGoogle Scholar
  46. 46.
    Bakshi R, Czarnecki D, Shaikh ZA, Priore RL, Janardhan V, Kaliszky Z, Kinkel PR (2000) Brain MRI lesions and atrophy are related to depression in multiple sclerosis. Neuroreport 11:1153–1158PubMedCrossRefGoogle Scholar
  47. 47.
    Codella M, Rocca MA, Colombo B, Rossi P, Comi G, Filippi M (2002) A preliminary study of magnetization transfer and diffusion tensor MRI of multiple sclerosis patients with fatigue. J Neurol 249:535–537PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • T. Hayton
    • 1
  • J. Furby
    • 1
  • K. J. Smith
    • 1
  • D. R. Altmann
    • 2
  • R. Brenner
    • 3
  • J. Chataway
    • 4
  • K. Hunter
    • 1
  • D. J. Tozer
    • 1
  • D. H. Miller
    • 1
  • R. Kapoor
    • 1
  1. 1.Department of NeuroinflammationInstitute of NeurologyLondonUK
  2. 2.London School of Hygiene and Tropical MedicineLondonUK
  3. 3.Department of NeurologyRoyal Free HospitalLondonUK
  4. 4.National Hospital for Neurology and NeurosurgeryLondonUK

Personalised recommendations